Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer Treatment's hidden heart risk under the microscope

NCT ID NCT04305613

Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 221 people with stage II or III lung cancer to see how chemoradiation therapy affects their heart health. Participants undergo heart scans, blood tests, and quality-of-life surveys before, during, and for at least two years after treatment. The goal is to better understand and detect heart damage early, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 221 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with lung cancer will be enrolled from the radiation oncology clinics at participating sites.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * Histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation * Able to give written informed consent Exclusion Criteria: * Pregnant or breast-feeding * Prior treatment with anthracyclines * Radiation treatment not expected to involve any heart exposure as determined by treating provider * ECOG performance status greater than 2 * Vulnerable patients, including pregnant women and prisoners * Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cardiotoxicity cardiovascular disorder lung cancer lung neoplasm non-small cell lung carcinoma radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiotoxicity Lung cancer stage II Lung cancer stage III Radiation toxicity

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Chester County Hospital

    West Chester, Pennsylvania, 19380, United States

  • Lancaster General Hospital

    Lancaster, Pennsylvania, 17601, United States

  • Montefiore Medical Center

    The Bronx, New York, 190467, United States

  • Rutger's University / Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08901, United States

  • The Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • University of Alabama

    Birmingham, Alabama, 35233, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.